company background image
RV7 logo

Halozyme Therapeutics DB:RV7 Stock Report

Last Price

€55.54

Market Cap

€7.6b

7D

4.4%

1Y

41.8%

Updated

08 May, 2025

Data

Company Financials +

Halozyme Therapeutics, Inc.

DB:RV7 Stock Report

Market Cap: €7.6b

RV7 Stock Overview

A biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. More details

RV7 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance5/6
Financial Health4/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Halozyme Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Halozyme Therapeutics
Historical stock prices
Current Share PriceUS$55.54
52 Week HighUS$60.68
52 Week LowUS$38.89
Beta1.26
1 Month Change1.42%
3 Month Change0.33%
1 Year Change41.76%
3 Year Change52.52%
5 Year Change152.45%
Change since IPO2,436.07%

Recent News & Updates

Recent updates

Shareholder Returns

RV7DE BiotechsDE Market
7D4.4%0.6%1.7%
1Y41.8%-12.2%12.8%

Return vs Industry: RV7 exceeded the German Biotechs industry which returned -12.2% over the past year.

Return vs Market: RV7 exceeded the German Market which returned 12.8% over the past year.

Price Volatility

Is RV7's price volatile compared to industry and market?
RV7 volatility
RV7 Average Weekly Movement4.9%
Biotechs Industry Average Movement5.9%
Market Average Movement6.3%
10% most volatile stocks in DE Market13.0%
10% least volatile stocks in DE Market3.1%

Stable Share Price: RV7 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: RV7's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998350Helen Torleyhalozyme.com

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.

Halozyme Therapeutics, Inc. Fundamentals Summary

How do Halozyme Therapeutics's earnings and revenue compare to its market cap?
RV7 fundamental statistics
Market cap€7.64b
Earnings (TTM)€429.06m
Revenue (TTM)€958.53m

17.8x

P/E Ratio

8.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RV7 income statement (TTM)
RevenueUS$1.08b
Cost of RevenueUS$258.42m
Gross ProfitUS$825.88m
Other ExpensesUS$340.52m
EarningsUS$485.36m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)3.94
Gross Margin76.17%
Net Profit Margin44.76%
Debt/Equity Ratio312.6%

How did RV7 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/08 14:23
End of Day Share Price 2025/05/07 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Halozyme Therapeutics, Inc. is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
James BirchenoughBarclays
Robert WassermanBenchmark Company